High TMB and T cell inflammation signature have been regarded as essential predictive biomarkers in immune checkpoint blockade therapy; however, a recent study revealed that these two markers have low correlation.23 Based on the present data, it is not clear whether high TMB XB type tumours are susceptible to anti-PD-1/PD-L1 therapy. This evidence concerns the gene PDCD1 and neoplasm.